Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patientXinghao Ai, Xiaomin Niu, Lianpeng Chang, et al.BMC Cancer|September 17, 2021
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trialXinghao Ai, Zhengbo Song, Hong Jian, et al.Molecular Biosystems|December 15, 2016
Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancerYingjia Sun, Xinghao Ai, Jingwen Hou, et al.Frontiers in Genetics|August 30, 2024
SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimationYanfang Guan, Zhengfa Xue, Jiayin Wang, et al.Cell Biology and Toxicology|June 17, 2025
Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survivalYin Li, Liliang Xia, Hui Wang, et al.Radiation Oncology (London, England)|September 16, 2021
Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trialJianjiao Ni, Yue Zhou, Lin Wu, et al.Science China. Life Sciences|February 13, 2021
Lactate anions participate in T cell cytokine production and functionJing Wen, Shipeng Cheng, Yaguang Zhang, et al.Nature Communications|August 22, 2024
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trialJianjiao Ni, Xiaofei Wang, Lin Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in ChinaZiming Li, Yongfeng Yu, Jiade Lu, et al.Therapeutic Advances in Medical Oncology|July 21, 2022
Comprehensive analysis of MET mutations in NSCLC patients in a real-world settingXinghao Ai, Yongfeng Yu, Jun Zhao, et al.Pageof 4